Acculis microwave tissue ablation system launched worldwide
7 January 2009
UK company Acculis Limited has announced the worldwide launch of its
pioneering microwave tissue ablation (MTA) system for the coagulation of
soft tissue in open surgery.
The MTA system is being used to treat liver cancers. It is the only
single-needle high power 2.45GHz microwave system cleared by the US FDA.
It achieves 5x6.5cm coagulations with single eight-minute applications
and 4.3x6cm diameter coagulations in only four minutes.
The MTA system surpasses contemporary low power 915 MHz microwave
systems which require complex multiple needle placements and longer
times to achieve equivalent coagulations.
The system was first distributed to a cohort of the world’s leading
cancer centres. The roll out is now being extended through the
recruitment of distributors in several European countries, South America
Stuart McIntyre, CEO of Acculis Limited said, “We are pleased to be
making this market-leading technology available to cancer centres
throughout the world. The MTA System has proven itself as an important
additional tool for the liver surgeon. It simplicity, power and speed
make it ideal for delivering fast large spherical coagulations in
conjunction with other intra-operative procedures. Other low power-low
frequency systems require multiple needles, complex placements, multiple
generators and are slow and costly. Unlike the MTA system, which meets
the needs of surgeons and administrators alike.”
Acculis says that the speed and predictability of MTA means that the
desired coagulation zone can be reliably and decisively achieved and the
short time taken to create large coagulations means that many more sites
can be coagulated within a given operative window. The simplicity of the
system ensures that ablations can be performed during open procedures
without placing complex additional equipment management demands on the
Bookmark this page